Resarch programme: RNA targeting small molecules - Contera Pharma/Vernalis Research
Latest Information Update: 10 Oct 2022
Price :
$50 *
At a glance
- Originator Contera Pharma; Vernalis
- Class Small molecules
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders
Most Recent Events
- 27 Sep 2022 Vernalis Research and Contera Pharma agree to co-promote and co-develop RNA targeting small molecules in Denmark and United kingdom for Neurological disorders
- 27 Sep 2022 Early research in Neurological disorders in Denmark (unspecified route)
- 27 Sep 2022 Early research in Neurological disorders in United Kingdom (unspecified route)